Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | INVA | Common Stock | Sale | -$392M | -32M | -100% | $12.25 | 0 | May 20, 2021 | See Footnote | F1, F2 |
GSK plc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Id | Content |
---|---|
F1 | Common stock sold pursuant to a share repurchase agreement by and between Glaxo Group Limited ("GGL"), an indirect wholly owned subsidiary of the Reporting Person, and Innoviva, Inc. (the "Issuer") dated as of May 20, 2021. |
F2 | Common Stock was held of record by GGL, an indirect wholly owned subsidiary of the Reporting Person. |